AstraZeneca Pharma India Limited has announced that its Board of Directors will meet on Tuesday, May 26, 2026. The primary agenda for the meeting includes the consideration and approval of the audited financial results for the company for the quarter and year ended March 31, 2026.

The board will also deliberate on recommending a dividend, if any, on the equity shares of the company for the financial year 2025-26. This decision will be subject to the approval of the shareholders.

In conjunction with the upcoming board meeting and the announcement of financial results, the company has informed the exchanges that the trading window for designated persons remains closed. This closure is effective from March 16, 2026, to May 28, 2026 (both days inclusive), in accordance with the company's Code of Conduct for Prevention of Insider Trading.

Key Meeting Details

The intimation was addressed to the Listing Managers at the National Stock Exchange of India Ltd. and BSE Limited. The communication was digitally signed by Tanya Sanish, Company Secretary & Compliance Officer.

AstraZeneca Pharma India Limited has secured shareholder approval for the shifting of its registered office from the State of Karnataka to the State of Maharashtra, along with a consequential amendment to the second clause of its Memorandum of Association (MOA). The Special Resolution was passed through a postal ballot process, with the voting results declared on May 12, 2026, by Company Secretary and Compliance Officer Tanya Sanish. Pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company intimated the stock exchanges of this development. The approval is subject to receipt of requisite regulatory approvals, including those under the Companies Act, 2013 and rules framed thereunder.

Postal Ballot Process and Voting Window

The postal ballot was initiated pursuant to a notice dated March 11, 2026, and members were invited to cast their votes electronically. The e-voting window was open from Sunday, April 12, 2026 (9:00 am IST) to Monday, May 11, 2026 (5:00 pm IST), through the National Securities Depository Limited (NSDL) e-voting platform at www.evoting.nsdl.com . The record date for determining eligible shareholders was April 3, 2026, on which date the total number of shareholders stood at 29,618. In accordance with applicable MCA Circulars, the postal ballot notice was sent in electronic form only, and all voting was conducted exclusively through the remote e-voting system. A total of 274 members (folio-wise) cast their votes through remote e-voting.

Scrutinizer Appointment and Report

Mr. Vijayakrishna K.T., Company Secretary in Whole-Time Practice (FCS No. 1788, CP No. 980), was appointed as Scrutinizer by the Company's Board at its meeting held on March 11, 2026. His report, issued on May 12, 2026, confirmed that the voting process was conducted in a fair and transparent manner. The scrutinizer's findings were based on data derived from the NSDL e-voting platform and covered votes cast by shareholders holding equity shares in both physical and electronic mode.

Voting Results

The Special Resolution was passed with requisite majority. The following table summarises the overall voting outcome as reported by the Scrutinizer:

The detailed category-wise breakdown of votes polled is presented below:

There were no invalid votes recorded across any shareholder category — Promoter and Promoter Group, Public Institutions, or Public Non-Institutions.

Key Details of the Resolution

• Resolution Type: Special Resolution
• Subject: Shifting of the registered office from the State of Karnataka to the State of Maharashtra and consequential amendment to the Memorandum of Association
• Promoter/Promoter Group Interest in Resolution: No
• Resolution Status: Passed

The voting results and the Scrutinizer's Report have been made available on the company's website at www.astrazeneca.com/india and on the NSDL e-voting website at www.evoting.nsdl.com , in compliance with applicable regulatory requirements.